Literature DB >> 10602413

Leukemogenesis by CBF oncoproteins.

A D Friedman1.   

Abstract

The AML1 and CBFbeta subunits of core binding factor (CBF) are involved in several chromosomal abnormalities frequently associated with acute leukemias. As a result, the CBFbeta-SMMHC, AML1-ETO and AML1-MDS1/EVI1 fusion proteins are expressed in subsets of acute myeloid leukemia, and TEL-AML1 is expressed in B-lineage acute lymphocytic leukemia. These CBF oncoproteins likely contribute to leukemogenesis in part by inhibiting endogenous CBF. As a result they are expected to inhibit differentiation and perhaps apoptosis. In addition, the domains unique to each fusion protein may also contribute to leukemogenesis via unique mechanisms.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10602413     DOI： 10.1038/sj.leu.2401590

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


  22 in total

Review 1.  Transcriptional regulation of myelopoiesis.

Authors:  Alan D Friedman
Journal:  Int J Hematol       Date:  2002-06       Impact factor: 2.490

2.  Multimerization via its myosin domain facilitates nuclear localization and inhibition of core binding factor (CBF) activities by the CBFbeta-smooth muscle myosin heavy chain myeloid leukemia oncoprotein.

Authors:  Tanawan Kummalue; Jianrong Lou; Alan D Friedman
Journal:  Mol Cell Biol       Date:  2002-12       Impact factor: 4.272

3.  Phosphorylation of RUNX1 by cyclin-dependent kinase reduces direct interaction with HDAC1 and HDAC3.

Authors:  Hong Guo; Alan D Friedman
Journal:  J Biol Chem       Date:  2010-11-08       Impact factor: 5.157

4.  Dichotomy of AML1-ETO functions: growth arrest versus block of differentiation.

Authors:  S A Burel; N Harakawa; L Zhou; T Pabst; D G Tenen; D E Zhang
Journal:  Mol Cell Biol       Date:  2001-08       Impact factor: 4.272

Review 5.  Cell cycle and developmental control of hematopoiesis by Runx1.

Authors:  Alan D Friedman
Journal:  J Cell Physiol       Date:  2009-06       Impact factor: 6.384

Review 6.  Molecularly targeted therapies for pediatric acute myeloid leukemia: progress to date.

Authors:  Patrick Brown; Franklin O Smith
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

7.  Acute myeloid leukemias with reciprocal rearrangements can be distinguished by specific gene expression profiles.

Authors:  Claudia Schoch; Alexander Kohlmann; Susanne Schnittger; Benedikt Brors; Martin Dugas; Susanne Mergenthaler; Wolfgang Kern; Wolfgang Hiddemann; Roland Eils; Torsten Haferlach
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-08       Impact factor: 11.205

8.  Runx1 Phosphorylation by Src Increases Trans-activation via Augmented Stability, Reduced Histone Deacetylase (HDAC) Binding, and Increased DNA Affinity, and Activated Runx1 Favors Granulopoiesis.

Authors:  Wan Yee Leong; Hong Guo; Ou Ma; Hui Huang; Alan B Cantor; Alan D Friedman
Journal:  J Biol Chem       Date:  2015-11-23       Impact factor: 5.157

Review 9.  C/EBPα in normal and malignant myelopoiesis.

Authors:  Alan D Friedman
Journal:  Int J Hematol       Date:  2015-03-10       Impact factor: 2.490

10.  Cyclin-dependent kinase phosphorylation of RUNX1/AML1 on 3 sites increases transactivation potency and stimulates cell proliferation.

Authors:  Linsheng Zhang; Florence B Fried; Hong Guo; Alan D Friedman
Journal:  Blood       Date:  2007-11-14       Impact factor: 22.113
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.